Physician profile
Irwin Hametz
NPI 1992720999
$4,285.27
in general payments reported to CMS, 2019-2025
28 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $125 · 2021: $178 · 2022: $252 · 2023: $535 · 2024: $1,175 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,872 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,871.76 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.92 | 2022-2025 | |
| Biofrontera INC. | $433.57 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Pfizer INC. | $350.98 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $343.90 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $335.70 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $252.87 | 2020-2024 | Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $252.27 | 2021-2024 | Dupixent |
| Galderma Laboratories, L.P. | $228.66 | 2019-2025 | Nemluvio |
| Amgen INC. | $204.59 | 2023-2025 | Otezla, Enbrel |
| Dermavant Sciences, INC. | $203.69 | 2023-2024 | Vtama |
| Leo Pharma INC. | $124.85 | 2019-2024 | Adbry |
| Verrica Pharmaceuticals INC. | $112.58 | 2024 | Ycanth |
| Organon LLC | $103.98 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $99.46 | 2019-2025 | Winlevi |
| Novartis Pharmaceuticals Corporation | $86.71 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $47.10 | 2021-2025 | |
| Incyte Corporation | $46.28 | 2023-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.36 | 2019 | |
| Botanix Sb INC | $32.19 | 2025 | Sofdra |
| Encore Dermatology INC. | $27.33 | 2019 | |
| Organogenesis INC. | $21.56 | 2025 | Affinity |
| Almirall LLC | $17.84 | 2024 | Seysara |
| Aclaris Therapeutics, INC. | $17.11 | 2019 | |
| Mission Pharmacal Company | $15.59 | 2019 | |
| Sebela Pharmaceuticals INC. | $14.03 | 2019 | |
| Celgene Corporation | $13.85 | 2019 | |
| Prugen, INC. Pharmaceuticals | $13.77 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.53 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irwin Hametz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.